• Home >>
  • Pharmaceuticals and Healthcare >>
  • Necrotizing Entrecolitis Market: Global Market Synopsis, Growth Factors, Industry Segmentation, Regional Analysis And Competitive Analysis 2017 - 2025

Necrotizing Entrecolitis Market: Global Market Synopsis, Growth Factors, Industry Segmentation, Regional Analysis And Competitive Analysis 2017 - 2025

ID: 240325 21st May, 2018 Region : Global Pages Reports Monitor

Market Scenario:

Necrotizing Enterocolitis or NEC is a devastating disease which affects usually the intestine of premature infants. In this disease, the wall of the intestine is attacked by bacteria, which can cause local infection and inflammation that can eventually destroy the wall of the intestine. The intestine or bowel wall damage can lead to opening of the intestine walls causing spillage of stool into the infant’s abdomen, this can result in a serious infection and death. The premature infants are generally the most vulnerable of this devastating disease. 


The improved reimbursement policies and framework in developed countries, unmet medical needs,  growing research funding, and increasing government assistance are continuously have immensely contributed to the growth of the global market. However, there are some issues associated with the necrotising enterocolitis market. The complications in the treatment of this disease, lack of skilled or trained physicians and doctors, and poor healthcare infrastructure in low and middle-income economies may hamper the growth of the global necrotizing entercolitis market. The government’s constant efforts to improve the healthcare infrastructure by making huge investments in healthcare sector can further enhance the market growth in the developing nations worldwide.


Market Segmentation:

The global necrotizing entercolitis market is segmented on the basis of stage which includes three stages, Stage I, Stage II, and Stage III. Stage II is furthermore bifurcated into Stage IIa and Stage IIb. The Stage III is further classified into Stage IIIa and Stage IIIb.

Moreover, the market is segmented on the basis of diagnosis such as imaging, laboratory studies, and differential diagnosis. Furthermore, on the basis of end- user market is segregated as hospitals and clinics, ambulatory surgical center, diagnostic centers, and others.

Furthermore, on the basis of treatment, the global necrotizing entercolitis market is classified as Total Parenteral Nutrition or TPN, gastrointestinal decompression, antifungal treatment, paracentesis, antimicrobial therapy, and Others.


Regional Analysis:

The global necrotizing entercolitis market is dominated by America owing well developed technology, high healthcare spending and presence of leading players. According to the report of Centers for Disease Control and Prevention in 2015, total health expenditure in the U.S. region moreover, presence of geriatric population and government support have fuelled the market growth in America. Europe accounts for the second leading market which is followed by Asia Pacific. Strong government support and favorable research policies have driven the growth of Europe market. Asia Pacific is the fastest growing market due to huge untapped opportunity for the development of the market. Rising government spending and increasing premature infant births in APAC can trigger the market in near future in countries like India, China, 

On the other hand, the Middle East & Africa holds the least share in the market due to presence of poor economies in Africa region.


Key Players:

The major key players in this market are Abbott Laboratories Inc., Astellas Pharma Inc., Bayer HealthCare AG, Becton, Dickinson and Company, Bristol-Myers Squibb Company, Daiichi Sankyo Company Ltd., Eli Lilly and Co., Enzon Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, GI Supply, GlaxoSmithKline Plc, Kyorin Pharmaceutical Co. Ltd., Medtronic Plc, Merck & Co. Inc., MiddleBrook Pharmaceuticals, Novartis AG, Pfizer Inc., Sanofi-Aventis (France), Sequana Medical AG, and Takeda Pharmaceutical Company Ltd.

Research Scope 

The study for Global Necrotizing Enterocolitis Market will provide market size, estimates and forecast based on the following years: 

 

Historic data: 2015  Base Year Estimate: 2016  Forecast: 2017 to 2025

The report has been categorized in two distinctive sections, where the first category titled as Market Overview provides a holistic view of the market, key trends, drivers, challenges/restraints or opportunities with their current and expected impact on the overall industry sales. 

Our analyst implement, several qualitative tools such as Ansoff’s Matrix, PESTEL analysis, Porter’s five force analysis among other to interpret and represent key industry findings. 

The second section of the study provides market size, estimates and forecast for key market segments and regional market. The final part of the report highlights key manufacturers/vendors operating in the associated market. 


1. Introduction

1.1. Market Definition

1.2. Market Scope

2. Research Methodology

2.1. Primary Research

2.2. Secondary Sources

2.3. Assumptions & Exclusions


3. Market Overview

3.1. Research Report Segmentation & Scope

3.2. Global Necrotizing Enterocolitis Market- Value Chain Analysis 

3.3. Key Market Trend Analysis

3.3.1. Market Drivers

3.3.2. Market Restraint/Challenges

3.3.3. Market Opportunities

3.4. Porter’s Five Forces Analysis

3.5. Potential Venture Avenues

3.6. Market Share Analysis, 2016 

3.7. Market Overview – Global Necrotizing Enterocolitis, Product Landscape


4. Segmentation Overview

4.1. Introduction 

4.2. Market Size & Forecast, 2015 to 2025

4.2.1. By stage

4.2.2.1. Stage I

4.2.2.2. Stage II (Stage IIa and Stage IIb)

4.2.2.3. Stage III (Stage IIIa and Stage IIIb)

4.2.2.  By diagnosis

4.2.2.1.  Imaging

4.2.2.2. Laboratory studies

4.2.2.3. Differential diagnosis Furthermore, on the basis of end- user market is segregated as hospitals and clinics, ambulatory surgical center, diagnostic centers, and others

4.2.3.   By end-user

4.2.3.1. Hospitals and clinics

4.2.3.2.  Ambulatory surgical center

4.2.3.3.  Diagnostic centers  

4.2.3.4. Others

(Note: The segments mentioned above are tentative in nature and are subject to change as the research progresses)


5. Regional Overview

5.1. Introduction

5.2. Market Size & Forecast, 2015 to 2025

5.2.1. North America 

5.2.1.1. U.S.

5.2.1.2. Canada

5.2.2. Europe

5.2.2.1. UK

5.2.2.2. Germany

5.2.2.3. France 

5.2.2.4. Rest of Europe

5.2.3. Asia Pacific

5.2.3.1. China 

5.2.3.2. India

5.2.3.3. Japan

5.2.3.4. Rest of Asia Pacific 

5.2.4. LAMEA

5.2.4.1. Brazil 

5.2.4.2. Argentina

5.2.4.3. Rest of LAMEA 

(Note: The segments mentioned above are tentative in nature and are subject to change as the research progresses)


6. Manufacturer/ Vendor Profile

6.1. The following attributes will be considered while profiling key manufacturers in this industry: 

6.1.1. Company Overview

6.1.2. Financial Synopsis

6.1.3. Recent Developments

6.1.4. R&D Investments (if any)

6.1.5. Strategy Overview (Analyst Perspective)

6.1.6. Product Portfolio

6.2. Companies Profiled

6.2.1.  Abbott Laboratories Inc.

6.2.2. Astellas Pharma Inc.

6.2.3. Bayer HealthCare AG

6.2.4. Becton

6.2.5.  Dickinson and Company

6.2.6. Bristol-Myers Squibb Company

6.2.7. Daiichi Sankyo Company Ltd.

6.2.8.  Eli Lilly and Co.

6.2.9.  Enzon Pharmaceuticals Inc.

6.2.10.  F. Hoffmann-La Roche Ltd

6.2.11.  GI Supply

6.2.12.  GlaxoSmithKline Plc

(Note: The companies mentioned above are tentative in nature, and profiles of other market players not listed here can be included on request.) 

Request Sample

Name*

Email*

Phone*

Name of the Company*

Title/ Designation*

Select Country*

How can we help you?

Request Discount

Name*

Email*

Phone*

Name of the Company*

Title/ Designation*

Select Country*

How can we help you?

Related Reports




Get 15 minutes of free Consultation When you request a Sample Report!

24/7 Research Report

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone:

+1 513 549 5911 (US)

+44 203 318 2846 (UK)

Email: [email protected]